Vilon
Vilon is a synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family, studied mainly through in vitro gene-expression and cell-culture experiments in aging human tissue, with proposed immunomodulatory and "geroprotective" effects that lack controlled human clinical trial support.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Vilon (Lys-Glu, also called the KE peptide) is proposed to act by binding directly to specific double-stranded DNA promoter sequences (identified via molecular docking as GCGG/GGGC motifs), thereby modulating expression of genes such as SIRT1, PARP1, and PARP2 that are implicated in cellular aging. This DNA-interaction model is the primary mechanism proposed by the Khavinson research group for Vilon's reported immunomodulatory and geroprotective effects, but it has not been broadly validated by independent laboratories.
Typical results seen in research
Reported effects come from in vitro and ex vivo human cell studies rather than clinical trials: cultured human mesenchymal stem cells treated with the KE peptide showed increased SIRT1 gene/protein expression and decreased PARP1/PARP2 expression during replicative aging; human periodontal ligament stem cells cultured with KE (combined with other short peptides) showed increased expression of neuronal differentiation markers; and chromatin studies in lymphocytes from elderly human donors (75-88 years) showed KE-induced decondensation of heterochromatin regions. These are laboratory-scale, non-blinded experiments from a small, closely linked group of researchers, not clinical outcome trials.
How it’s commonly used
In the Russian bioregulator research tradition, Vilon has historically been administered via injection courses; in the laboratory studies reviewed here it was applied directly to isolated human cell cultures rather than given to research subjects.
- Advances in Gerontology (Uspekhi Gerontologii) · 2023 KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
- Georgian Medical News · 2023 Epigenetic Modification Under the Influence of Peptide Bioregulators on the "Old" Chromatin
- International Journal of Immunopathology and Pharmacology · 2019 Effect of short peptides on neuronal differentiation of stem cells
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.